A “two-for-one” cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report today in the journal Nature Medicine.
Mount Sinai researchers identify the structure of a special red blood cell transporter
Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how
September 8, 2023